Ichthammol 1% / Clioquinol 3% in Hydrocortisone 1% ointment
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 48 studies.
1942–2025
Showing all 48 studies, sorted by most relevant.
Oxford English Dictionary, 2023
Sanjay Kumar *, K. Biradar, S. M, et al.
Journal of Clinical Otorhinolaryngology, 2023
Shyamala K, Mohana Karthikeyan S, Sheetal K
Cureus, 2024
Oxford English Dictionary, 2023
Jeferson Luis Franco
Advances in Clinical Toxicology, 2023
Saai Ram Thejas, Sindu Mohan, Bathula Deepthi
Indian Journal of Otology, 2025
Abstract Background: Acute Otitis Externa (AOE) is diffuse inflammation of the external auditory canal. Findings show a narrowed, tender and erythematous external auditory canal. There are no concrete methods in the management of AOE. Current methods include aural toileting and application of topical agents. Betamethasone Valerate, a Corticosteroid and 0.1% w/w of drug is used most commonly. The commercially used 10% Ichthammol Glycerin solution is a mixture of pure Glycerol [C3H8O3] in a 9:1 ratio with Ichthammol. Methods: All patients presenting to the Department of Otorhinolaryngology of a Rural Hospital in South India diagnosed with AOE between were included in study. Thirty were assigned to each group. Group A had IG and Group B had BV placed in their ear canal with the help of a sterile cotton wick at 0, 24 and 48 hour. The Visual Analogue Scale and Edema Erythema Index were used as parameters of assessment. Results: The EET improvement stood at 51.31% in Group A. The EET improvement stood at 47.96% in Group B. In Group A, VAS had an improvement of 63.85%. In Group B, VAS had an improvement of 49.42%. Conclusion: The use of IG was found to be superior to BV in the management of AOE. IG provides relief from topical allergy and irritation along with reduction of edema. Since IG is cheaper and easy to procure, it can be used as a first line treatment in the management of AOE.
Abstract licence: CC BY-NC-SA 4.0
M. Ahmed, A. Michael, S. Hassan, et al.
European Journal of Chemistry, 2021
Minnu Thomas
Journal of Medical Science And clinical Research, 2016
CABI Compendium, 2017
Chemical Effects in Biological Systems (CEBS), 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.